Question-and-Answer Session
Thank you. The floor is now open for questions. [Operator Instructions]. Our first question comes from Greg Gilbert of Merrill Lynch. Please state your question.
Gregory Gilbert - Merrill Lynch
Thanks. Good morning. Can you give us your latest thoughts on the competitive environment in the Thrombin market and whether you are assuming growth in that product going forward?
Brian A. Markison - Chairman, President and Chief Executive Officer
Yes. Thanks, Greg, good morning, it's Brian. Number one, I think we are doing a pretty good job competing in the Thrombin market with a lot of new noise and new competition. I think growth in the market should be expected by virtue of the fact that there is more than just King out there promoting the product. And I think growth is Thrombin-JMI is going to be very difficult as we go forward. But, I think the team on a King side is doing a tremendous job holding the forth with what we have.
Gregory Gilbert - Merrill Lynch
On Avinza, can you update us on the patent challenge front there and any life cycle management initiative ongoing there?
Brian A. Markison - Chairman, President and Chief Executive Officer
Certainly the patent challenge is proceeding, we are still in the early days of discovery really nothing new to tell you there. The other parts of life cycle management for Avinza we have number of clinical trials that are ongoing that we hope to see some early results than actually distant future. Some encouraging data, but in terms of the formulations front there is nothing exciting going on there.
Gregory Gilbert - Merrill Lynch
And lastly before I get back in line Brian are we beyond the 60 days point from the REMOXY filing and is that a significant data point in this environment?
Brian A. Markison - Chairman, President and Chief Executive Officer
Greg, thanks. I believe the magic day could be tomorrow. But if your are looking at 60 days and we are hopeful that we are going to get some reasonably good news.
Gregory Gilbert - Merrill Lynch
Thanks.
Operator
Thank you. Our next question is from Corey Davis of Natixis. Please state your question.
Corey Davis - Natixis Bleichroeder
Just thanks for clarifying that because I think in the direct press release they said the FDA has 90 days to accept the remarks to be filing but, it's my understanding that it's always been 60. So thanks for that clarification? And secondly are you conducting any the likeability types studies on REMOXY or ACUROX kind of things that the panel had asked for.
- To read the full transcript on Seeking Alpha, click here »
